tetano
Editor, Senior Moderator
Bioelectrochemistry
. 2022 May 25;147:108161.
doi: 10.1016/j.bioelechem.2022.108161. Online ahead of print.
Development of sandwich electrochemiluminescence immunosensor for COVID-19 diagnosis by SARS-CoV-2 spike protein detection based on Au@BSA-luminol nanocomposites
Morteza Hosseini[SUP] 1 [/SUP], Ebtesam Sobhanie[SUP] 2 [/SUP], Foad Salehnia[SUP] 2 [/SUP], Guobao Xu[SUP] 3 [/SUP], Hodjattallah Rabbani[SUP] 4 [/SUP], Mahsa Naghavi Sheikholeslami[SUP] 5 [/SUP], Ali Firoozbakhtian[SUP] 2 [/SUP], Niloufar Sadeghi[SUP] 4 [/SUP], Mohammad Hossein Farajollah[SUP] 6 [/SUP], Mohammad Reza Ganjali[SUP] 5 [/SUP], Houman Vosough[SUP] 6 [/SUP]
Affiliations
Abstract
Coronavirus disease (COVID-19) is a new and highly contagious disease posing a threat to global public health and wreaking havoc around the world. It's caused by the Coronavirus that causes severe acute respiratory syndrome (SARS-CoV-2). In the current pandemic situation, rapid and accurate SARS-CoV-2 diagnosis on a large scale is critical for early-stage diagnosis. Early detection and monitoring of viral infections can aid in controlling and preventing infection in large groups of people. Accordingly, we developed a sensitive and high-throughput sandwich electrochemiluminescence immunosensor based on antigen detection for COVID-19 diagnosis (the spike protein of SARS-CoV-2). For the spike protein of SARS-CoV-2, the ECL biosensor had a linear range of 10 ng mL[SUP]-1[/SUP] to 10 µg mL[SUP]-1[/SUP] with a limit of detection of 1.93 ng mL[SUP]-1[/SUP]. The sandwich ECL immunosensor could be used in early clinical diagnosis due to its excellent recovery in detecting SARS-CoV-2, rapid analysis (90 min), and ease of use.
Keywords: Au@BSA-luminol; COVID-19; Electrochemiluminescence; SARS-CoV-2; Sandwich immunosensor.
. 2022 May 25;147:108161.
doi: 10.1016/j.bioelechem.2022.108161. Online ahead of print.
Development of sandwich electrochemiluminescence immunosensor for COVID-19 diagnosis by SARS-CoV-2 spike protein detection based on Au@BSA-luminol nanocomposites
Morteza Hosseini[SUP] 1 [/SUP], Ebtesam Sobhanie[SUP] 2 [/SUP], Foad Salehnia[SUP] 2 [/SUP], Guobao Xu[SUP] 3 [/SUP], Hodjattallah Rabbani[SUP] 4 [/SUP], Mahsa Naghavi Sheikholeslami[SUP] 5 [/SUP], Ali Firoozbakhtian[SUP] 2 [/SUP], Niloufar Sadeghi[SUP] 4 [/SUP], Mohammad Hossein Farajollah[SUP] 6 [/SUP], Mohammad Reza Ganjali[SUP] 5 [/SUP], Houman Vosough[SUP] 6 [/SUP]
Affiliations
- PMID: 35659688
- DOI: 10.1016/j.bioelechem.2022.108161
Abstract
Coronavirus disease (COVID-19) is a new and highly contagious disease posing a threat to global public health and wreaking havoc around the world. It's caused by the Coronavirus that causes severe acute respiratory syndrome (SARS-CoV-2). In the current pandemic situation, rapid and accurate SARS-CoV-2 diagnosis on a large scale is critical for early-stage diagnosis. Early detection and monitoring of viral infections can aid in controlling and preventing infection in large groups of people. Accordingly, we developed a sensitive and high-throughput sandwich electrochemiluminescence immunosensor based on antigen detection for COVID-19 diagnosis (the spike protein of SARS-CoV-2). For the spike protein of SARS-CoV-2, the ECL biosensor had a linear range of 10 ng mL[SUP]-1[/SUP] to 10 µg mL[SUP]-1[/SUP] with a limit of detection of 1.93 ng mL[SUP]-1[/SUP]. The sandwich ECL immunosensor could be used in early clinical diagnosis due to its excellent recovery in detecting SARS-CoV-2, rapid analysis (90 min), and ease of use.
Keywords: Au@BSA-luminol; COVID-19; Electrochemiluminescence; SARS-CoV-2; Sandwich immunosensor.